A New Approach to Primary Prevention of Cardiovascular Disease

American Journal of Medicine

Volumn 120, Issue 9, 2007, Pages 746-747

  Kostis, John B ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; EDITORIAL; HEALTH PROGRAM; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; UNITED STATES;

CARDIOVASCULAR DISEASES; HUMANS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS;

EID: 34548162060     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.02.019     Document Type: Editorial

References (15)

1. American Heart Association. Heart disease and stroke statistics 2006 update. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3018163. Accessed January 29, 2007.
2. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 24 (1997) 1498-1504
3. Ong K.L., Cheung B.M.Y., Man Y.B., et al. Prevalence, awareness, treatment, and control of hypertension among United States adults. 1999-2004. Hypertension 49 (2007) 69-75 :1
4. O'Meara J.G., Kardia S.L., Armon J.J., et al. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 164 (2004) 1313-1318
5. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 13 1 Pt 2 (2000) 3S-10S
6. Kostis JB. Treating hypercholesterolemia and hypertension based on lifetime global risk. Am J Cardiol. In press.
7. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001) 2486-2497
8. Jackson P.R. The influence of absolute cardiovascular risk, patient utilities and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertension 21 (2003) 1631-1634
9. Cohen J.C., Boerwindle E., Mosley Jr. T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006) 1264-1272
10. Brown M.S., and Goldstein J.L. Lowering LDL-not only how low, but how long?. Science 311 (2006) 1721-1723
11. Hippocrates. Epidemics, Book. I, Sect. V.
12. Baron J. Do no harm. In: Messick D.M., and Tenbrunsel A.E. (Eds). Codes of Conduct: Behavioral Research into Business Ethics (1996), Russell Sage Foundation, New York, NY 197-213
13. Emanuel E.J., and Wertheimer A. Who should get influenza vaccine when not all can?. Science 312 (2006) 854-855
14. Anderson G.F., and Chu E. Expanding priorities-confronting chronic disease in countries with low income. N Engl J Med 356 (2007) 209-211 :3
15. Kostis J.B. Disputation on the use of age in determining the need for treatment of hypercholesterolemia and hypertension. J Clin Hypertens 8 (2006) 519-520